The management of severe alcoholic liver disease and variceal bleeding in the intensive care unit

Current Opinion in Critical Care

Volumn 12, Issue 2, 2006, Pages 171-177

  Berry, Philip A ^a   Wendon, Julia A ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Albumin dialysis; Alcoholic hepatitis; Hepatorenal syndrome; Portal hypertension; Transjugular intrahepatic portosystemic shunt; Variceal haemorrhage

Indexed keywords

MIDODRINE; OCTREOTIDE; OFLOXACIN; TERLIPRESSIN;

ABDOMINAL CRAMP; ALBUMIN DIALYSIS; ALCOHOL LIVER DISEASE; CLINICAL TRIAL; DISEASE SEVERITY; ESOPHAGUS VARICES BLEEDING; HEART ARRHYTHMIA; HEPATORENAL SYNDROME; HUMAN; INFECTION; INTENSIVE CARE; INTENSIVE CARE UNIT; LIVER SUPPORT; MORTALITY; PATHOPHYSIOLOGY; PATIENT CARE; PROGNOSIS; REVIEW; RISK BENEFIT ANALYSIS; TREATMENT INDICATION;

ESOPHAGEAL AND GASTRIC VARICES; GASTROINTESTINAL HEMORRHAGE; HOSPITAL MORTALITY; HUMANS; INTENSIVE CARE UNITS; LIVER DISEASES, ALCOHOLIC; MIDDLE AGED; PORTASYSTEMIC SHUNT, TRANSJUGULAR INTRAHEPATIC; RANDOMIZED CONTROLLED TRIALS; SEVERITY OF ILLNESS INDEX;

EID: 33645318158     PISSN: 10705295     EISSN: 15317072     Source Type: Journal    
DOI: 10.1097/01.ccx.0000216587.62125.24     Document Type: Review

References (46)

1. Carithers RL Jr, Herlong HF, Diehl AM, et al. Methylprednisolone therapy in patients with severe alcoholic hepatitis. A randomised multicenter trial. Ann Int Med 1989; 110:685-690.
2. Forrest EH, Evans CDJ, Stewart S, et al. Analysis of factors predictive of mortality in alcoholic hepatitis and derivation and validation of the Glasgow alcoholic hepatitis score. Gut 2005; 54:1174-1179. A newly developed, prospectively validated scoring system to assess the severity and prognosis in alcoholic hepatitis.
3. Ramond MJ, Poynard T, Rueff B, et al. A randomised trial of prednisolone in patients with severe alcoholic hepatitis. N Engl J Med 1992; 326:507-512.
4. Mathurin P, Abdelnour M, Ramond M, et al. Early change in bilirubin levels is an important prognostic factor in severe alcoholic hepatitis treated with prednisolone. Hepatology 2003; 38:1363-1369.
5. Naveau S, Chollet-Martin S, Dharancy S, et al. Foie-Alcool group of the Association Francaise pour l'etude du Foie. A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Hepatology 2004; 39:1390-1397. An important negative trial.
6. Cabre E, Rodriguez-Iglesias P, Caballeria J, et al. Short- and long-term outcome of severe alcohol-induced hepatitis treated with steroids or enterai nutrition: a multicentre randomised trial. Hepatology 2000; 32:36-42.
7. Alvarez MA, Cabre E, Lorenzo-Zuniga V, et al. Combining steroids with enterai nutrition: a better therapeutic strategy for severe alcoholic hepatitis? Results of a pilot study. Eur J Gastroenterol Hepatol 2004; 16:1375-1380. A small study reinforcing an earlier trial that compared feeding with steroids; this develops a combined approach, and the possibility of a tapering steroid regimen.
8. Wiest R, Garcia-Tsao G. Bacterial translocation (BT) in cirrhosis. Hepatology 2005; 41:423-433.
9. Lee SS. Cardiac dysfunction in spontaneous bacterial peritonitis: a manifestation of cirrhotic cardiomyopathy [Editorial]. Hepatology 2003; 38:1089-1091.
10. Lenz K. Hepatorenal syndrome - is it central hypovolaemia, a cardiac disease, or part of gradually developing multiorgan dysfunction? [Editorial] Hepatology 2005; 42:263-265.
11. Ruiz-del-Arbol L, Urman J, Fernandez J, et al. Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology 2003; 38:1210-1218.
12. Ruiz-del-Arbol L, Monesillo A, Arocena C, et al. Circulatory function and hepatorenal syndrome in cirrhosis. Hepatology 2005; 42:439-447. A substantial (66 patients) study of systemic and hepatic haemodynamic parameters, concluding that cardiac output plays an important role in the onset of HRS.
13. Quinlan GJ, Martin GS, Evans TW. Albumin: biochemical properties and therapeutic potential. Hepatology 2005; 41:1211-1219. A comprehensive review of the properties of albumin.
14. Finfer S, Bellomo R, Boyce N, et al. SAFE Study Investigators. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med 2004; 350:2247-2256.
15. Vincent JL, Navickis RJ, Wilkes MM. Morbidity in hospitalized patients receiving human albumin: a meta-analysis of randomised, controlled trials. Crit Care Med 2004; 32:2029-2038.
16. Sort P, Navasa M, Arroyo V, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999; 341:403-409.
17. Ortega R, Gines P, Uriz J, et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, non-randomised study. Hepatology 2002; 36:941-948.
18. Fernandez J, Navasa M, Garcia-Pagan JC, et al. Effect of intravenous albumin on systemic and hepatic hemodynamics and vasoactive neurohormonal systems in patients with cirrhosis and spontaneous bacterial peritonitis. J Hepatol 2004; 41:384-390. An uncontrolled study documenting improvements in haemodynamic status after resolution of SBP, attributed to albumin.
19. Fernández J, Monteagudo J, Bargallo X, et al. A randomized unblinded pilot study comparing albumin versus hydroxyethyl starch in spontaneous bacterial peritonitis. Hepatology 2005; 42:627-634. An eagerly awaited trial showing specific haemodynamic advantages with albumin as compared to 'plain' colloid.
20. Moreau R, Durand F, Poynard T, et al. Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicentre study. Gastroenterology 2002; 122:923-930.
21. Solanki P, Chawla A, Garg R, et al. Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomised placebo-controlled clinical trial. J Gastroenterol Hepatol 2003; 18:152-156.
22. Wong F, Pantea L, Sniderman K. Midodrine, octreotide, albumin and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology 2004; 40:55-64. A novel study effecting a permanent reversal of renal impairment, with TIPSS, in patients with HRS who respond to medical therapy.
23. Heeman U, Treichel U, Loock J, et al. Albumin dialysis in cirrhosis with superimposed acute liver injury: a prospective controlled study. Hepatology 2002; 36:949-958.
24. Mitzner SR, Stange J, Klammt S, et al. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomised, controlled clinical trial. Liver Transplant 2000; 6:277-286.
25. Jalan R, Sen S, Steiner C, et al. Extracorporeal liver support with molecular adsorbents recirculating system in patients with severe acute alcoholic hepatitis. J Hepatol 2003; 38:24-31.
26. Khuroo MS, Khuroo MS, Farahat KLC. Molecular adsorbent recirculating system for acute and acute-on-chronic liver failure: a meta-analysis. Liver Transplant 2004; 10:1099-1106.
27. Kamath PS. Is there life on MARS? Hepatology 2002; 36:1017-1019.
28. John GR, Lee SC, Brosnan CF. Cytokines: powerful regulators of glial cell activation. Neuroscientist 2003; 9:10-22.
29. Rolando N, Wade J, Davalos M, et al. The systemic inflammatory response syndrome in acute liver failure. Hepatology 2000; 32:734-739.
30. Shawcross DL, Davies NA, Williams R, Jalan R. Systemic inflammatory response exacerbates the neuropsychological effects of induced hyperammonaemia in cirrhosis. J Hepatol 2004; 40:247-254. An elegant ward-based study correlating the physiological parameters of inflammation with encephalopathy.
31. Sen S, Davies NA, Mookerjee RP, et al. Pathophysiological effects of albumin dialysis in acute-on-chronic liver failure: a randomised controlled study. Liver Transplant 2004; 10:1109-1119. A comparison of MARS versus standard medical care in 18 randomly assigned patients with AoCLF, documenting clinical improvements without expected reductions in inflammatory markers.
32. Blei AT. Albumin dialysis for the treatment of hepatic encephalopathy. J Gastroenterol Hepatol 2004; 19:S224-S228.
33. Doria C, Mandala L, Smith JD, et al. Thromboelastography used to assess coagulation during treatment with molecular adsorbent recirculating system. Clin Transplant 2004; 18:365-371. An important corroboration of anecdotally observed coagulation abnormalities observed during MARS therapy.
34. Rifai K, Ernst T, Kretschmer U, et al. Prometheus - a new extracorporeal system for the treatment of liver failure. J Hepatol 2003; 39:984-990.
35. O'Grady JG, Gimson AE, O'Brien CJ, et al. Controlled trials of charcoal hemoperfusion and prognostic factors in fulminant hepatic failure. Gastroenterology 1988; 94:1186-1192.
36. Krisper P, Haditsch B, Stauber R, et al. In vivo quantification of liver dialysis: comparison of albumin dialysis and fractionated plasma separation. J Hepatol 2005; 43:451-457. An early report of efficacy relating to a novel extracorporeal support device.
37. de Franchis R. Evolving consensus in portal hypertension - report of the Baveno IV Consensus Workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol 2005; 43:167-176.
38. Carbonell N, Pauwels A, Serfty L, et al. Improved survival after variceal bleeding in patients with cirrhosis over the past two decades. Hepatology 2004; 40:652-659. An interesting analysis of factors leading to improved outcomes.
39. Bosch J, Thabut D, Bendtsen F, et al. Recombinant factor VIIa for upper gastrointestinal bleeding in patents with cirrhosis: a randomised, double-blind trial. Gastroenterology 2004; 127:1123-1130. A superficially negative study, although subgroup analysis may lead to further investigation of this expensive treatment in most severely cirrhotic patients.
40. Goulis J, Armonis A, Patch D, et al. Bacterial infection is independently associated with failure to control bleeding in cirrhotic patients with gastrointestinal hemorrhage. Hepatology 1998; 27:1207-1212.
41. Chau TN, Chan YW, Patch D, et al. Thromboelastographic changes and early rebleeding in cirrhotic patients with variceal bleeding. Gut 1998; 43:267-271.
42. Thalheimer U, Triantos C, Samonakis D, et al. Endogenous heparinoids in acute variceal bleeding. Gut 2005; 54:310-311.
43. Goulis J, Patch D, Burroughs AK. Bacterial infection in the pathogenesis of variceal bleeding. Lancet 1999; 353:13-42.
44. Hou MC, Lin HC, Liu TT, et al. Antibiotic prophylaxis after endoscopic therapy prevents rebleeding in acute variceal haemorrhage: a randomised trial. Hepatology 2004; 39:746-753. An important clinical trial confirming the link between infection and a tendency to re-bleed after initial haemostasis.
45. Moitinho E, Escorsell A, Bandi JC, et al. Prognostic value of early measurements of portal pressure in acute variceal bleeding. Gastoenterology 1999; 117:626-631.
46. Monescillo A, Martinez-Lagares F, Ruiz-del-Arbol L, et al. Influence of portal hypertension and its early decompression by TIPS placement on the outcome of variceal bleeding. Hepatology 2004; 40:793-801. A logistically impressive, well-sized interventional study resulting in improved outcome after variceal haemorrhage.